Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes (PREDICTIVE™)

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT00655044

NN304-3514

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Enrollment: 3,637 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 1 diabetes
• Type 2 diabetes
• Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion criteria

• Unwilling to adhere to therapy or follow up
• Pregnancy

Trial design

3,637 participants in 1 patient group

Type 1 and type 2 diabetes patients

Treatment:

Drug: insulin detemir